Immune checkpoint inhibitor-related pneumonitis in lung cancer: real-world incidence, risk factors, and management practices across six health care centers in North Carolina

RECOMMENDED

Pleural Diseases

Immune Checkpoint Inhibitor and Radiotherapy-Related Pneumonitis: An Informatics Approach to Determine Real-World Incidence, Severity, Management, and Resource Implications

★ 2 Recommended by Dr Martin Frey, Faculty Member

★ 1 Recommended by Dr Marcus Hesse, Faculty Member

Front Med (Lausanne)

Hindocha S, Campbell D, Ahmed M, Giorgakoudi K, Sharma B, Yousaf N, Molyneaux P, Hunter B, Kalsi H, Cui W, Davidson M, Bhosle J, Minchom A, Locke I, McDonald F, O'Brien M, Popat S, Lee RW

doi: 10.3389/fmed.2021.764563

RECOMMENDED

Lung CancerPleural DiseasesFurther Publications

Immune checkpoint immunotherapy for non-small cell lung cancer: benefits and pulmonary toxicities

Chest.

Suresh K, Naidoo J, Lin CT, Danoff S

doi: 10.1016/

RECOMMENDED

Lung Cancer

ECOG performance status ≥2 as a prognostic factor in patients with advanced non small cell lung cancer treated with immune checkpoint inhibitors-A systematic review and meta-analysis of real world data

Lung Cancer.

Dall'Olio FG, Maggio I, Massucci M, Mollica V, Fragomeno B, Ardizzoni A

doi: 10.1016/j.lungcan.2020.04.027.

RECOMMENDED

Lung Cancer

Two-year survival with nivolumab in previously treated advanced non-small-cell lung cancer: A real-world pooled analysis of patients from France, Germany, and Canada

★ 2 Recommended by Dr Martin Frey, Faculty Member

★ 1 Recommended by Dr Marcus Hesse, Faculty Member

Lung Cancer

Debieuvre D, Juergens RA, Asselain B, Audigier-Valette C, Auliac JB, Barlesi F, Benoit N, Bombaron P, Butts CA, Dixmier A, Gröschel A, Gutz S, Labbé C, Moro-Sibilot D, Pérol M, Raspaud C, Schumann C, Juarez-Garcia A, Lakhdari K, Pettersson F, Penrod JR, Reynaud D, Waldenberger D, Allan V, Sebastian M

doi: 10.1016/j.lungcan.2021.04.022

COMMENTED

Lung Cancer

Incidence of second and higher order smoking-related primary cancers following lung cancer: a population-based cohort study

Thorax.

Barclay ME, Lyratzopoulos G, Walter FM, Jefferies S, Peake MD, Rintoul RC

doi: 10.1136/thoraxjnl-2018-212456.

RECOMMENDED

Lung Cancer

Risk Factors Associated with a Second Primary Lung Cancer in Patients with an Initial Primary Lung Cancer

★ 1 Recommended by Dr Martin Frey, Faculty Member

Clin Lung Cancer

Fisher A, Kim S, Farhat D, Belzer K, Milczuk M, French C, Mamdani H, Sukari A, Baciewicz F, Schwartz AG, Wozniak A, Nagasaka M

doi: 10.1016/j.cllc.2021.04.004

RECOMMENDED

Lung Cancer

The Impact of Beta Blockers on Survival Outcomes in Patients With Non-small-cell Lung Cancer Treated With Immune Checkpoint Inhibitors

★ 1 Recommended by Dr Martin Frey, Faculty Member

Clin Lung Cancer.

Oh MS, Guzner A, Wainwright DA, Mohindra NA, Chae YK, Behdad A, Villaflor VM

doi: 10.1016/j.cllc.2020.07.016.

RECOMMENDED

Lung Cancer

Real-World Outcomes for Advanced Non-Small Cell Lung Cancer Patients Treated With a PD-L1 Inhibitor Beyond Progression

★ 2 Recommended by Dr Martin Frey, Faculty Member

★ 2 Recommended by Dr Marcus Hesse, Faculty Member

Clin Lung Cancer.

Stinchcombe TE, Miksad RA, Gossai A, Griffith SD, Torres AZ

doi: 10.1016/j.cllc.2020.04.008.

RECOMMENDED

Interstitial Lung Disease

Closing the Evidence Gap in Interstitial Lung Disease: The Promise of Real World Data

Am J Respir Crit Care Med.

Farrand E, Anstrom KJ, Bernard G, Butte AJ, Iribarren C, Ley B, Martinez F, Collard HR

doi: 10.1164/rccm.

Related content

Immune Checkpoint Inhibitor and Radiotherapy-Related Pneumonitis: An Informatics Approach to Determine Real-World Incidence, Severity, Management, and Resource Implications

Immune checkpoint immunotherapy for non-small cell lung cancer: benefits and pulmonary toxicities

ECOG performance status ≥2 as a prognostic factor in patients with advanced non small cell lung cancer treated with immune checkpoint inhibitors-A systematic review and meta-analysis of real world data

Two-year survival with nivolumab in previously treated advanced non-small-cell lung cancer: A real-world pooled analysis of patients from France, Germany, and Canada

Incidence of second and higher order smoking-related primary cancers following lung cancer: a population-based cohort study

Risk Factors Associated with a Second Primary Lung Cancer in Patients with an Initial Primary Lung Cancer

The Impact of Beta Blockers on Survival Outcomes in Patients With Non-small-cell Lung Cancer Treated With Immune Checkpoint Inhibitors

Real-World Outcomes for Advanced Non-Small Cell Lung Cancer Patients Treated With a PD-L1 Inhibitor Beyond Progression

Closing the Evidence Gap in Interstitial Lung Disease: The Promise of Real World Data